Year End Rally Cry

[00:00:00] Stacey Richter: Hello, all you Relentless Tribe members. This episode today is meant to be a ray of kind of like, "Yes, we can do this.” And I'm going here today because generally speaking, it's the end of the year with Thanksgiving, the holiday season, and it's kind of a time of reflection and regrouping and storing up our nuts and berries, hoping some of them can grow into trees next year.

That metaphor has some problems, but yeah, you get the drift.

A Past Win Against HMOs

[00:00:33] Stacey Richter: But I just wanna take a pause to remind everybody that 30 years ago, some big, powerful actors in the USA healthcare industry engaged in some fairly obvious and fairly egregious financial engineering and got torn to the ground by a group of smart, motivated activists.

And I mention this because it's proof that it can be done. So right, this show today is meant to be a yes we can, we can do this thing, positive reinforcement, and it's also a thank you.

Thank you for all that you've done, Relentless Tribe, and thanks in advance for all that you're going to accomplish.

Because, yeah, we got this. It might be a longer and messier and far more grueling battle than we may have thought going in, but yeah.

Alex Jung Clip Setup

[00:01:25] Stacey Richter: So what I'm gonna do here is play Alex Jung sharing what amounts to a success story, one that I don't hear mentioned a lot. This was part of an episode that aired in 2018, and it is still extremely relevant.

So I'm gonna play this clip from the show with Alex Jung, and then I'm gonna come back to finish out my time with you with a few thoughts. But let me let Alex Jung tell the story first.

You know, one of the things that you had mentioned the last time that we spoke was that approximately 30 years ago, change was created at that time by a social force.

How HMOs Denied AIDS Drugs

[00:02:05] Alex Jung: Yeah, a lot of people through the years that we had HMOs. I grew up in the industry when we had hundreds and hundreds of HMOs in the United States, and they were an instrument that was intended to save money. If you don't know what they are, they were organizations that took a capitated price from an employer, particularly self-insured employer space, but even in the government agency space where Medicare and Medicaid were using HMOs.

And one of the things that HMOs used to do was they would narrow the networks of the provider you could choose. They would require pre-authorizations and referrals, and/or to get access to certain drugs, and they would control costs by putting in restrictions and utilization barriers.

During the time that they were the dominant health insurance policy design in the United States, we also saw an epidemic of HIV and AIDS, and drug companies were developing these that would help mitigate the, not only the symptoms, but slow down the progression of HIV AIDS.

And unfortunately, because those drugs were expensive, there were lots of restrictions put around their use. Some drug companies would release or launch a product that could help with AIDS, and the HMOs would refuse to pay for it because they thought it was too expensive, or they would consider it a noncovered benefit because it was an experimental therapy.

What ended up happening was the prevailing policy in these HMOs was to deny coverage for those drugs, and unfortunately, people started dying.

Lawsuits That Brought HMOs Down

[00:03:35] Alex Jung: The AIDS community got very organized around this effort and started filing lawsuits across the country, many of which made it to state judicial systems, and a lot of those plaintiffs were found to be in the right, and the HMOs were found to be in the wrong, and they had to pay massive settlements.

Those massive settlements caused liquidity and bankruptcy of some of the larger HMOs around the United States because they were liable for denying a claim. The juries that decided those cases awarded some pretty significant awards to the families of the deceased patients.

Now, the AIDS community has been very organized for many years. It was the first time we saw a disease-specific social advocacy group, create a consolidated response in the marketplace that challenged the practices station management in healthcare.

We're going to start to see that again as the new drugs that are in the pipeline start getting launched, particularly those that might have potential for curing serious diseases like cancer or rare diseases.

Today's Denials and Litigation

[00:04:36] Stacey Richter: What is the equivalent today of what happens when all those HMOs liquidated back in the nineties?

[00:04:43] Alex Jung: Well, we haven't seen too much of it yet, but we are beginning to see patients sue for denial of coverage, and there is obviously a remedy for that. You do have the opportunity to appeal a denial in a healthcare plan, but that denial has to be based on, you know, a pretty solid foundation of decision-making criteria.

The problem with the system today is it's not transparent. So it's difficult for people to understand what criteria was used to deny the claim. Was it necessity or clinical efficacy that drove the decision, or was it economic, purely economic, that it was just too expensive and we don't want to pay for it?

So we are starting to see social media that are sharing information with one another and encouraging one another to file class action lawsuits. And of course, the plaintiffs' attorneys see this as an opportunity. Companies that at one time went after the tobacco industry are now looking at the healthcare industry as a fertile ground for plaintiff litigation because they see the same kinds of abuses, all of which are centered on nontransparent business practices.

We Can Do It Again

[00:05:43] Stacey Richter: Yeah, the cool thing about having a 12-year back catalog is that when I think something is relevant again, I might have an episode that we already talked about it.

And I say that because right now, across the country, there is a mounting wave of outrage over double-digit health plan renewals, opaque coverage denials, high deductibles that leave families functionally uninsured.

And when people feel trapped by a $4.9 trillion system, it is easy to assume that change is impossible, that the behemoth is simply intractable, too big to fail

But yeah, we've done this before. And that means that we can have some confidence that we can do it again. But it also means we have to be careful about two things.

Number one, how we communicate, and also to take stock of some of maybe the operational lessons that we can learn from the first time.

Lessons From Capitation

[00:06:39] Stacey Richter: To both of these ends, in an, I don't know, I hope great minds think alike coincidence, as I was in the middle of getting my act together for this episode, I happened to see Dr. William Bestermann's Substack pop into my inbox. Timing could not have been more perfect. Here's what he had to say.

He wrote, "Why 1990s HMOs failed and how audited concurrent goals finally align clinician pay with human health.” That's the headline of the Substack. And by the way, I'm only gonna read a part of it. Here is the full article.

"Mention the word capitation to any physician who practiced medicine in the 1990s, and you will evoke an immediate visceral shudder. To a generation of doctors and patients, capitation was the dark heart of the managed care HMO era. It conjures memories of insurance gatekeepers, denied specialist referrals, rationed MRI scans, and financial arrangements that paid physicians more money to simply withhold care.

Doctors felt like insurance company sentries forced to say no to their own patients while patients felt abandoned by a system that seemed to profit from their suffering.”

Hmm, that sounds a little familiar.

"Capitation became a four-letter word in American healthcare. In response, the nation retreated back into the comforting familiar arms of traditional fee-for-service medicine. That retreat was a catastrophic mistake.”

In the article, Dr. Bestermann gets into greater detail on the how do we do a new kind of, “capitation” that isn't make your primary care doctor a gatekeeper who is sort of tasked with preventing patients from getting to a specialist who might prescribe an expensive drug or therapy or procedure.

Messaging Matters

[00:08:27] Stacey Richter: So what that means is we've gotta be really careful about our language and how we communicate. As I said, that's the first thing that we have to be careful of. Because if you talk to a room full of physicians or you talk to a room full of patients or members and you start talking about, "Hey, let's go back to let's improve the primacy of primary care,” someone in the audience is gonna raise their hand, and I say this from experience, and say, "Wait, what do you mean? We're gonna go back to a time when you have to go to a primary care doctor who's gonna be a gatekeeper?" Right? Immediately people's heads are gonna go there, so it's really important. The messaging here is very important. That's the first point that I would make.

Define What We Want

[00:09:04] Stacey Richter: Which leads me to my next maybe point to ponder as we contemplate our future.

We can't just figure out what we don't want. We have to be clear about what we do want. And I'm gonna go back to something that Dr. Eric Bricker said in the recent podcast with him. He said, "No one is coming to save us.” Talking about plan sponsors, talking about really patients, members, and he's probably also talking about physicians.

No one is coming to save us. And what that means is that the Relentless Tribe, you who listen to this show, please really think about not only what we don't want, but also what we do. And there's a number of Relentless Tribe members who are doing all kinds of really amazing work to that end.

Get Purchasers and Patients Involved

[00:09:51] Stacey Richter: But I would also remind you that there are currently big tent think tanks who are coming up with healthcare reform ideas.

And you know who's not in that big tent? Purchasers, or at least at any level. And also not a whole lot of patients, members. Right?

So I just wanna remind everyone that those who take money in the healthcare industry are never probably going to willingly... It's like the innovator's dilemma, right? They're never gonna design a plan where they make less.

And relying fully on policymakers, and there are some great policymakers out there, but most policy members have never paid for or delivered care. And they might also have a little problem with regulatory capture.

So let's just make sure that those of you who listen to this show, especially in this moment of time when there's a lot of discussion about what is gonna be the next thing, please make sure that we are contemplative of being in the right place at the right time and being in these conversations as we consider the go forward.

We can do this. As Alex Jung explained, we've done this in the past. There has been a reckoning before. But what we did not do before, really, is really carefully think through what now. And that's what we have the opportunity to do.

Closing Thanks and Sponsors

[00:11:24] Stacey Richter: Thank you so much for listening. Thank you so much for being here. Thank you so much even more for all of the work that you do on behalf of patients and members.

My name is Stacey Richter. This podcast is sponsored by Aventria Health Group. Thank you so much to Payerset, our series sponsor in 2026. Thank you so much to Patient Rights Advocate for their lovely financial donation to help keep this show on the air. Thank you.